Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial …
Category:
Investing
-
-
Investing
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx Addressing Patients with Recurrent Pericarditis
by adminCardiol Therapeutics President and CEO, David Elsley PRISM MarketView announces the release of an informative …
-
-
-
-
-
-
-
-
